GlassScriptPhysician profile
Melinda Vickers
NPI 1164019345
$1,627.03
in general payments reported to CMS, 2019-2025
20 companies · $586 in 2025
The $586 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $155 · 2022: $196 · 2023: $434 · 2024: $256 · 2025: $586.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,276.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,276.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $221.25 | 2021-2025 | Jakafi, Niktimvo |
| Janssen Biotech, INC. | $188.47 | 2022-2025 | Carvykti, Tecvayli, Darzalex |
| Abbvie INC. | $187.59 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $166.40 | 2023-2024 | |
| Adaptive Biotechnologies Corporation | $117.90 | 2022 | |
| Sobi, INC | $114.03 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $103.20 | 2025 | |
| Jazz Pharmaceuticals INC. | $80.73 | 2025 | |
| Legend Biotech USA INC. | $58.45 | 2025 | Carvykti |
| Janssen Scientific Affairs, LLC | $49.54 | 2023-2025 | Tecvayli, Talvey |
| Celgene Corporation | $48.78 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.42 | 2025 | Livtencity, Iclusig |
| Merck Sharp & Dohme LLC | $43.49 | 2021-2025 | Prevymis |
| Daiichi Sankyo INC. | $43.43 | 2025 | Vanflyta |
| Taiho Oncology, INC. | $33.66 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $33.06 | 2025 | |
| Kite Pharma, INC. | $30.38 | 2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $20.59 | 2022 | |
| Astellas Pharma US INC | $19.73 | 2025 | Xospata |
| Pfizer INC. | $18.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Vickers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.